Search - tctmd.com

Displaying 21 - 40 of 452

Sort: Relevancy | Date

Presentation TCT 2016

Introduction and Session Objectives

Presenter: Dariusz Dudek, Petr Kala

October 30, 2016

Presentation TCT 2016

Czech Republic Presents: How Did I Treat This Case?

Presenter: Eric Van Belle, Jochen Wöhrle, Marian Branny

October 30, 2016

Presentation TCT 2016

Poland Responds: How Would I Treat This Case?

Presenter: Eric Van Belle, Jochen Wöhrle, Marek Grygier

October 30, 2016

Presentation TCT 2016

Czech Republic Presents: A Case of Ostial LAD Undergoing TAVR: Staged or Single Procedure?

Presenter: Eric Van Belle, Jochen Wöhrle, Marian Branny

October 30, 2016

Presentation TCT 2016

France Presents: How Did I Treat This Case?

Presenter: Eric Van Belle, Jochen Wöhrle, Flavien Vincent

October 30, 2016

Presentation TCT 2016

France Presents: A Patient With Critical CAD and Aortic Stenosis Undergoing TAVR: Staged or Single Procedure?

Presenter: Eric Van Belle, Jochen Wöhrle, Flavien Vincent

October 30, 2016

Presentation TCT 2016

Poland Presents: Treatment Options - Should Severe Coronary Artery Disease Be Treated Prior, During, or After TAVR (and in a Single or Staged Procedure)?

Presenter: Eric Van Belle, Jochen Wöhrle, Dariusz Dudek

October 30, 2016

Presentation TCT 2016

Introduction and Session Objectives

Presenter: Eric Van Belle, Jochen Wöhrle

October 30, 2016

News Conference News TCT 2016

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Yael L. Maxwell

October 29, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

News Conference News PCR London Valves 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Yael L. Maxwell

July 12, 2016

News Industry News

Essential Medical Inc. Announces FDA Approval to Begin a U.S. Clinical Trial for the MANTA™ Large Bore Vascular Closure Device

July 08, 2016

Advertisement

Introduction and Session Objectives

Czech Republic Presents: How Did I Treat This Case?

Poland Responds: How Would I Treat This Case?

Czech Republic Presents: A Case of Ostial LAD Undergoing TAVR: Staged or Single Procedure?

France Presents: How Did I Treat This Case?

France Presents: A Patient With Critical CAD and Aortic Stenosis Undergoing TAVR: Staged or Single Procedure?

Poland Presents: Treatment Options - Should Severe Coronary Artery Disease Be Treated Prior, During, or After TAVR (and in a Single or Staged Procedure)?

Introduction and Session Objectives

Transcaval TAVR Presents New Option for Patients With Complex Anatomy

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Essential Medical Inc. Announces FDA Approval to Begin a U.S. Clinical Trial for the MANTA™ Large Bore Vascular Closure Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content